At the time of writing, Xeris Biopharma Holdings Inc [XERS] stock is trading at $4.92, down -3.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The XERS shares have gain 6.03% over the last week, with a monthly amount glided 20.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on November 11, 2024, when Piper Sandler downgraded its rating to a Neutral but kept the price target unchanged to $3 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on March 28, 2024, and set its price target to $5. On August 28, 2023, Craig Hallum initiated with a Buy rating and assigned a price target of $4.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $4 on October 21, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $6.50 as its price target on April 28, 2022. SVB Leerink started tracking with a Outperform rating for this stock on November 17, 2021, and assigned it a price target of $6. In a note dated October 29, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
For the past year, the stock price of Xeris Biopharma Holdings Inc fluctuated between $1.86 and $6.07. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $4.92 at the most recent close of the market. An investor can expect a potential drop of -18.7% based on the average XERS price forecast.
Analyzing the XERS fundamentals
According to Xeris Biopharma Holdings Inc [NASDAQ:XERS], the company’s sales were 222.55M for trailing twelve months, which represents an 47.94% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is 1.6 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-7.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Xeris Biopharma Holdings Inc [NASDAQ:XERS] has a current ratio of 1.72. On the other hand, the Quick Ratio is 1.17, and the Cash Ratio is 0.61. Considering the valuation of this stock, the price to sales ratio is 3.54.
Transactions by insiders
Recent insider trading involved Fairley Ricki Louise, Director, that happened on May 09 ’25 when 56667.0 shares were purchased., Hecht Beth completed a deal on Mar 20 ’25 to sell 40000.0 shares. Meanwhile, Officer Hecht Beth bought 40000.0 shares on Mar 20 ’25.
